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INTRODUCTION
Infectious mononucleosis is common among adolescents and 
young adults.1 Although most cases resolve spontaneously, several 
life-threatening manifestations have been recognized. No guidelines 
for management of mononucleosis have been published. However, 
the American Academy of Pediatrics recommends that a short course 
of corticosteroid therapy may be considered for certain serious 
complications such as impending airway obstruction, massive sple-
nomegaly, hemolytic anemia, hemophagocytic lymphohistiocytosis, 
or myocarditis.2 Although some physicians prescribe prednisone for 
symptomatic treatment of other manifestations of mononucleosis, 
such as sore throat without airway obstruction, a recent Cochrane 
review identified no apparent benefit of steroid therapy for uncompli-
cated mononucleosis3; such treatment is not recommended despite 
its widespread use. 
Sinusitis is a well-recognized complication of viral infections 
,including mononucleosis. Corticosteroid therapy, even when only 
prescribed for brief periods, increases the risk of a variety of bacte-
rial, viral, mycobacterial, and parasitic infections by 60%.4 Fardet et 
al. reported a 5.84-fold increased relative hazard of lower respira-
tory tract infections among patients who received systemic steroid 
treatment for any reason (the prevalence of upper respiratory tract 
infections including sinusitis was not studied).5
Arcanobacterium haemolyticum is a slowly growing, facultative 
anaerobic gram-positive bacillus.6 Originally named Corynebacterium 
haemolyticum when recognized as a cause of exudative pharyngitis in 
US soldiers and natives of the South Pacific in 1946, the organism’s 
name was changed to Arcanobacterium haemolyticum in 1982 after 
cell wall components and chemotaxonomic features were noted to 
differ from Corynebacterium spp. Humans are the primary reser-
voir for A. haemolyticum, which has two biotypes, rough and smooth. 
The smooth biotype is a cause of pharyngitis in healthy adolescents 
whereas the rough biotype is associated with a variety of invasive 
infections which are more commonly seen in immunocompromised 
adults.6 The aptly-named Arcanobacterium (“secret bacterium”) is 
difficult to cultivate with conventional culture techniques (i.e., incu-
bation of specimens on sheep’s blood agar for 24 hours). One study 
reported that yield was highest when horse blood agar was utilized 
and specimens were incubated with supplemental 5% CO2 incuba-
tion for 48 hours.7 However, community laboratories do not typically 
use horse blood agar; thus the true prevalence of Arcanobacterium 
infections is likely higher than has been reported.
We report a case of Epstein-Barr Virus (EBV) mononucleosis 
treated with prednisone complicated by secondary bacterial sinusitis 
with intracranial extension leading to brain abscesses and subdu-
ral empyema, associated with Arcanobacterium bacteremia. To our 
knowledge this is the first report of EBV-associated Arcanobacte-
rium haemolyticum brain abscess and subdural empyema.
CASE REPORT
A previously healthy 20-year-old African American male college 
football player developed sore throat, fatigue, and painful cervical 
lymphadenopathy. The diagnosis of infectious mononucleosis was 
established on the basis of a positive heterophile antibody test. One 
week later he had worsening sore throat and headache. Prednisone 
was prescribed for 10 days. Over the following two weeks he had 
recurrent fevers, chills, malaise, anorexia, and insomnia, but delayed 
seeking further medical attention because he was busy taking final 
examinations. His symptoms progressively worsened. 
Three days prior to hospitalization he developed global headache, 
copious green rhinorrhea, recurrent rigors, and severe anorexia. He 
presented at a hospital emergency department where he appeared 
acutely ill. Posterior cervical lymph nodes were swollen and tender. 
No pharyngeal erythema or exudate was noted. No focal deficits were 
identified on neurologic examination.
His white blood cell count (WBC) was 16,300/µL (64% neutro-
phils, 24% bands, 7% monocytes, 5% lymphocytes). Total bilirubin 
was 5.7 U/L (direct 4.0 U/L), AST 410 U/L, ALT 290 U/L, and 
alkaline phosphatase 331 U/L. Epstein Barr virus viral capsid IgM 
serology was positive; viral capsid IgG serology was negative. 
Computerized tomography scan of the head without contrast 
showed pansinusitis without intracranial masses, edema, or midline 
shift. Cerebrospinal fluid WBC count was 2,800/ µL (46% neutro-
phils, 44% lymphocytes), glucose 44 mg/dL, and protein 100 mg/
dL. Gram’s stain showed no organisms; culture, which was submitted 
prior to initiation of antibiotic therapy, was negative. Cerebrospinal 
fluid EBV PCR was positive (not quantified); 16s RNA was negative.
The patient was hospitalized and treated with ceftriaxone, doxycy-
cline, and vancomycin. Doxycycline was discontinued after four days. 
Two of two sets of blood cultures grew Arcanobacterium haemolyti-
cum; identification of the organism was confirmed by Matrix-assisted 
laser desorption/ionization (MALDI TOF) testing. Over the follow-
ing four days the patient complained of worsening headache. MRI 
scan of the brain, with gadolinium, on hospital day five demonstrated
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temporal lobe and posterior inferior left frontal lobe, consistent with 
abscesses, and a subdural fluid collection in the anterior and inferior 
left cranial fossa (Figure 1). Metronidazole was added to his treat-
ment regimen.
Figure 1. MRI scan of the brain, with gadolinium, demonstrated multilocular 
fluid collections with enhancing margins in the left temporal lobe and pos-
terior inferior left frontal lobe, and a subdural fluid collection in the anterior 
and inferior left cranial fossa. 
The patient underwent image-guided pterional craniotomy with 
evacuation of frontal and temporal brain abscesses and removal of 
subdural empyema. Purulent fluid was encountered. Gram’s stain 
showed few polymorphonuclear leukocytes and rare gram positive 
bacilli with morphology characteristic of Arcanobacterium; culture 
was negative. He also underwent bilateral maxillary antrostomy, total 
ethmoidectomy, frontal sinusotomy, sphenoidotomy, sinus irrigation, 
and submucosal reduction of the inferior turbinates. Thick mucopu-
rulent fluid was encountered. Culture was negative.
Following evacuation of the brain abscesses and subdural 
empyema, the patient’s clinical status improved substantially. His 
fever and headaches abated. He received a nine-week course of 
intravenous ceftriaxone and metronidazole. Repeat imaging at the 
completion of his treatment demonstrated resolution of intracranial 
abscesses. His infection has not recurred during a two-year follow-up 
period.
DISCUSSION
We report a case of EBV mononucleosis treated with prednisone 
complicated by secondary bacterial sinusitis with intracranial exten-
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sion leading to brain abscesses and subdural empyema, associated 
with Arcanobacterium bacteremia. The dominant causative organism 
of the brain abscess and subdural empyema likely was Arcanobacte-
rium: although abscess culture was negative following several days 
of antibiotic therapy, abscess fluid Gram’s stain showed only gram 
positive bacilli with an appearance consistent with Arcanobacterium. 
We postulate that EBV infection caused disruption of upper respira-
tory tract epithelium, triggering secondary bacterial sinusitis with 
subsequent contiguous spread of infection to the brain and subdural 
space in the setting of transient immunosuppression precipitated by 
EBV and exacerbated by prednisone therapy. To our knowledge, this 
is the first report of EBV-associated Arcanobacterium haemolyticum 
brain abscess and subdural empyema. 
Pharyngitis is the most commonly recognized form of A. haemo-
lyticum infection.8 In half of cases a prominent erythematous rash 
is seen. Arcanobacterium accounts for 2% of cases of pharyngitis in 
15 - 18 year old healthy males. Several other forms of Arcanobacte-
rium infection have been reported, including sinusitis9, pneumonia10, 
bacteremia11, meningitis12, and brain abscess.10,13-15 Bacteremia is rare. 
Two cases were identified during a 15-year period at the Karolinska 
Institute.16 A similar experience was reported at Ben Taub Hospital 
in Houston, where among 280,000 blood cultures from 2000 - 2015, 
only two grew Arcanobacterium.13 Skin and soft tissue infections typ-
ically are seen in older men who either are immunocompromised or 
have an underlying disease such as diabetes mellitus.10, 16
The association of life-threatening Arcanobacterium infection 
with a concomitant Epstein Barr virus infection was of interest in our 
case. In invasive infections such as brain abscess, bacteremia, pneu-
monia, and Lemierre’s syndrome, A. haemolyticum typically acts as 
a co-pathogen with other bacteria or viruses, for reasons that remain 
unclear.11,14,17 Monomicrobial invasive Arcanobacterium infections, in 
contrast, are uncommon. In a retrospective study, all six patients with 
Arcanobacterium bacteremia were found to have co-infection with a 
second bacterial species.18 The second bacterium presumably acted 
synergistically with A. haemolyticum to enhance its pathogenicity.
Although both Epstein Barr Virus mononucleosis and A. hae-
molyticum pharyngitis are encountered most commonly in persons 
between the ages of 15 - 24, concomitant infection has been recog-
nized infrequently.9,14,19-21 Three cases of A. haemolyticum bacteremia 
with primary EBV infection have been reported, one of which had 
secondary bacterial sinusitis and polymicrobial bacteremia.20 
However, this association may be more common than has been 
widely recognized. A study of 13 patients with A. haemolyticum 
bacteremia detected heterophile antibody positivity in five cases.9 
Secondary bacterial infections (most commonly caused by beta 
hemolytic streptococci) are known to be associated with EBV, likely 
due to either temporary immune suppression or co-pathogenicity.22,23 
Thus, transient humoral and cell mediated immunosuppression 
induced by EBV may enhance A. haemolyticum’s virulence.9,14,21,23,24 
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Steroid-induced immunosuppression would be expected to exacer-
bate the severity of EBV-Arcanobacterium coinfection. 
Brain abscess can be caused by bacteria, mycobacteria, fungi, or 
parasites, and most commonly arises from either contiguous spread 
of infection, hematogenous seeding, penetrating trauma, or neuro-
surgical procedures.25 A variety of bacteria can cause brain abscesses; 
the implicated organisms vary based on the initial source of infec-
tion. Brain abscesses secondary to sinusitis, as in this case, usually 
are caused by anaerobic and aerobic streptococci, Bacteroides, E. 
coli, Enterobacter, Klebsiella, Proteus, S. aureus or Haemophilus.23 
However in 13 - 25% of cases, brain abscess cultures are negative, 
likely secondary to antecedent antibiotic exposure or infection with 
non-cultivable microorganisms.23,25 Arcanobacterium haemolyticum 
is a rare cause of brain abscess; only six cases have been reported pre-
viously. Two of these cases were presumed odontogenic infections 
(one occurred post-dental extraction; a second patient had severe 
dental caries;17 a third occurred after penetrating skull trauma in a 
patient with acute sinusitis.15 The sources of the other three infections 
were not identified.14,24,25
The optimal treatment regimen for invasive A. haemolyticum 
infections has not been determined. Susceptibility testing is not stan-
dardized. In vitro data suggest that A. haemolyticum is susceptible 
to most classes of antibiotics, including penicillins, cephalosporins, 
clindamycin, carbapenems, macrolides, fluoroquinolones, tetracy-
clines, rifampin, and vancomycin, and resistant to sulfonamides.26 
First line therapy with either penicillin or a cephalosporin is recom-
mended. In β-lactam allergic patients, alternative options include 
clindamycin, doxycycline, fluoroquinolones, or vancomycin. Our 
patient had an excellent response to ceftriaxone therapy.
CONCLUSION 
Arcanobacterium hemolyticum bacteremia, brain abscesses, and 
subdural empyema developed in a young man with concomitant EBV 
mononucleosis complicated by sinusitis who received prednisone 
therapy. The association between EBV and Arcanobacterium may 
be more common than previously recognized, as Arcanobacterium 
is a slowly growing organism that does not propagate well on com-
monly utilized sheep’s blood agar. Treatment with prednisone may 
have complicated our patient’s infection by exacerbating transient 
immunosuppression caused by EBV infection. Ceftriaxone therapy, in 
combination with surgical drainage, was effective in curing the brain 
abscesses, subdural empyema, and sinusitis. Arcanobacterium should 
be included in the differential diagnosis of brain abscesses in ado-
lescents and young adults. Steroid therapy for uncomplicated EBV 
mononucleosis should be used with caution as transient immunosup-
pression may increase the risk for serious bacterial complications, 
including brain abscess.
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